[Review of International Clinical Trials in the Field of Cardiology Reported in 2016].

We present in this article the review of 6 scientific Hot Line sessions of the 2016 European Congress of Cardiology devoted to novel approaches to treatment of heart failure, strategies of prevention of complications of cardiovascular diseases, dyslipidemia, imaging methods of investigation, and stenting in coronary heart disease.

[Congress of European Society of Cardiology (London, 2015): Results of Most Important Clinical Trials].

Report on all six Hot Line sessions of the European Society of Cardiology Congress, 2015, is presented. These sessions were doted to studies in acute myocardial infarction, atrial fibrillation/cardiac electrical pacing, diabetes/pharmacotherapy, arterial hypertension, heart failure, and coronary artery disease.

[Comparative Evaluation of -blockers and If-Channel Inhibitor in Patients With Chronic Heart Failure and Preserved Left Ventricular Ejection Fraction].

Treatment of patients with chronic heart failure (CHF) and preserved left ventricular (LV) ejection fraction remains largely empirical, as none of the methods of therapy improves the prognosis of patients. In a prospective randomized study on 126 patients with CHF and LV ejection fraction more or equal 50% we compared effectiveness of long-term treatment with bisoprolol (n=62) and ivabradine (n=64). Assessment of clinical status, exercise tolerance (ET), quality of life, blood level of N-terminal brain natriuretic peptide precursor, and parameters of echocardiography was performed at baseline and after 12 months of therapy.

[COMPARATIVE EFFECTIVENESS AND SAFETY OF NEW ORAL ANTICOAGULANTS AND WARFARIN IN PATIENTS WITH AGE-SPECIFIC NON-VALVULAR ATRIAL FIBRILLATION].

This study was designed to compare effectiveness and safety of warfarin, direct thrombin inhibitor dabigatran, Xa factor inhibitors rivaroxaban and apixaban used to prevent stroke in 280 elderly patients in patients with age-specific non-valvular atrial fibrillation. The treatment of patients aged 65-74 and 75-80 yearsfor 2 years with dab itragan (110 mg b.i.

[Comparison of Novel Oral Anticoagulants and Warfarin in Elderly Patients With Nonvalvular Atrial Fibrillation].

We compared efficacy and safety of warfarin with those of direct thrombin inhibitor dabigatran, factor Xa inhibitors rivaroxaban and apixaban used for stroke prevention in 280 patients aged 65-80 years with non-valvular atrial fibrillation. Treatment for two years with dabigatran (110 mg twice daily), apixaban (5 mg twice daily) or rivaroxaban (20 mg/day) prevented strokes no less successfully than warfarin, but more rarely caused severe intracranial hemorrhages. When selecting antithrombotic therapy in geriatric patients with non-valvular AF new oral anticoagulants may be regarded as an acceptable alternative to warfarin.